The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review
HER2 is mutated in 2-4% of non-small cell lung cancers (NSCLC) and is associated with poor prognosis. Tyrosine kinase inhibitors (TKIs) targeting HER2 have historically been hampered by insufficient efficacy against exon 20 insertion mutations and lack of specificity, resulting in off-target adverse...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
18 Feb 2026
|
| In: |
Expert review of anticancer therapy
Year: 2026, Pages: 1-11 |
| ISSN: | 1744-8328 |
| DOI: | 10.1080/14737140.2026.2623059 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1080/14737140.2026.2623059 |
| Author Notes: | John V. Heymach, Sanjay Popat, Egbert F. Smit, Petros Christopoulos, David Planchard, Tatsuya Yoshida, Jon Zugazagoitia, Yan Yu and Birgit Wilding |
Search Result 1
Search Result 2
Search Result 3